Chronic Idiopathic Urticaria Pipeline Insight, Clinical Trials Analysis, FDA Approvals 2023 | Major Companies- United BioPharma, Teva Pharmaceuticals Development Inc, Amgen, Novartis Pharmaceuticals, Allakos Inc., and Others

DelveInsight's, "Chronic Idiopathic Urticaria Pipeline Insight 2023" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Chronic Idiopathic Urticaria pipeline landscape. It covers the Chronic Idiopathic Urticaria pipeline drug profiles, including Chronic Idiopathic Urticaria clinical trials and nonclinical stage products. It also covers the Chronic Idiopathic Urticaria therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Chronic Idiopathic Urticaria Pipeline Report

• DelveInsight's Chronic Idiopathic Urticaria pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Chronic Idiopathic Urticaria treatment.

• The leading Chronic Idiopathic Urticaria Companies include United BioPharma, Teva Pharmaceuticals Development Inc, Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP., Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, Servier, and others

• Promising Chronic Idiopathic Urticaria Pipeline Therapies include Omalizumab, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine, Dupilumab SAR231893, non sedating H1-antihistamine, Levocetirizine, Desloratadine, Dupilumab, and others

• The Chronic Idiopathic Urticaria companies and academics are working to assess challenges and seek opportunities that could influence Chronic Idiopathic Urticaria R&D. The Chronic Idiopathic Urticaria therapies under development are focused on novel approaches to treat/improve Chronic Idiopathic Urticaria.

To explore more information on the latest breakthroughs in the Chronic Idiopathic Urticaria Pipeline treatment landscape of the report, click here @ Chronic Idiopathic Urticaria Pipeline Outlook- https://www.delveinsight.com/sample-request/chronic-idiopathic-urticaria-ciu-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Idiopathic Urticaria Overview
Chronic Urticaria (CU) conventionally refers to recurrent wheals, on most days of the week, which occur for a period of ≥ six weeks. CU can be further divided into two different subtypes, namely, Chronic Idiopathic Urticaria (CIU) (also called chronic spontaneous urticaria) and chronic inducible urticaria (also called physical urticaria). In most patients, CU is a sporadic and self-limited disorder.

Chronic Idiopathic Urticaria Emerging Drugs Profile

• Dupilumab: Sanofi
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.
Dupixent is approved for use in certain patients with atopic dermatitis, asthma, CRSwNP or EoE in different age populations. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including chronic spontaneous urticaria, which is in the Phase III developmental stage.

• Barzolvolimab: Celldex Therapeutics
Barzolvolimab (CDX-0159) is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival, and activity of mast cells. In certain inflammatory diseases, mast cell activation plays a central role in the onset and progression of the disease. Currently, the drug is being evaluated in the Phase II development stage for the treatment of chronic spontaneous urticaria.

• Lirentelimab: Allakos
Lirentelimab (AK002) is an afucosylated, humanized IgG1 monoclonal antibody that activates the inhibitory receptor Siglec-8. Additionally, lirentelimab depletes eosinophils via antibody-dependent cellular cytotoxicity (ADCC) in the blood. Siglec-8 is found on the surface of mature mast cells and mature eosinophils and therefore offers a way to selectively target these two cells. Siglec-8 exerts its inhibitory signal through an intracellular portion of the protein called the immunoreceptor tyrosine-based motif (ITIMs). Subcutaneously lirentelimab is currently being tested in a Phase IIb clinical trial in patients with chronic spontaneous urticarial; data from this study is expected in the second half of 2023.

Request a sample and discover the recent advances in Chronic Idiopathic Urticaria Ongoing Clinical Trial Analysis and Medications, click here @ Chronic Idiopathic Urticaria Treatment Landscape- https://www.delveinsight.com/sample-request/chronic-idiopathic-urticaria-ciu-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Idiopathic Urticaria Pipeline Therapeutics Assessment
There are approx. 20+ key companies which are developing the therapies for Chronic Idiopathic Urticaria. The companies which have their Chronic Idiopathic Urticaria drug candidates in the most advanced stage, i.e. phase III include, Sanofi.

Chronic Idiopathic Urticaria Pipeline Segmentation
Phases

DelveInsight's report covers around 22+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Chronic Idiopathic Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type
Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

For further information, refer to the detailed Chronic Idiopathic Urticaria Unmet Needs, Chronic Idiopathic Urticaria Market Drivers, and Market Barriers, click here for Chronic Idiopathic Urticaria Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/chronic-idiopathic-urticaria-ciu-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Idiopathic Urticaria Pipeline Report

• Coverage- Global

• Chronic Idiopathic Urticaria Companies- United BioPharma, Teva Pharmaceuticals Development Inc, Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP., Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, Servier, and others

• Chronic Idiopathic Urticaria Pipeline Therapies- Omalizumab, H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist, Diphenhydramine, Dupilumab SAR231893, non sedating H1-antihistamine, Levocetirizine, Desloratadine, Dupilumab, and others

• Chronic Idiopathic Urticaria Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Chronic Idiopathic Urticaria Market Drivers and Chronic Idiopathic Urticaria Market Barriers, click here @ Chronic Idiopathic Urticaria Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/chronic-idiopathic-urticaria-ciu-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Chronic Idiopathic Urticaria: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Idiopathic Urticaria- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Dupilumab: Sanofi
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Barzolvolimab: Celldex Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Chronic Idiopathic Urticaria Key Companies
21. Chronic Idiopathic Urticaria Key Products
22. Chronic Idiopathic Urticaria- Unmet Needs
23. Chronic Idiopathic Urticaria- Market Drivers and Barriers
24. Chronic Idiopathic Urticaria- Future Perspectives and Conclusion
25. Chronic Idiopathic Urticaria Analyst Views
26. Chronic Idiopathic Urticaria Key Companies
27. Appendix

Got Queries? Find out the related information on Chronic Idiopathic Urticaria Mergers and acquisitions, Chronic Idiopathic Urticaria licensing activities @ Chronic Idiopathic Urticaria Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/chronic-idiopathic-urticaria-ciu-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91 9568243403
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.